11970 related articles for article (PubMed ID: 11305184)
1. [Treatment of metastasized malignant melanoma].
Kamanabrou D
Praxis (Bern 1994); 2001 Mar; 90(10):391-6. PubMed ID: 11305184
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
[TBL] [Abstract][Full Text] [Related]
3. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
Flaherty LE
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S15-20. PubMed ID: 10685653
[TBL] [Abstract][Full Text] [Related]
4. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.
Legha SS
Semin Oncol; 1997 Feb; 24(1 Suppl 4):S39-43. PubMed ID: 9122733
[TBL] [Abstract][Full Text] [Related]
5. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P
J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391
[TBL] [Abstract][Full Text] [Related]
6. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
7. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
Lewis KD; Robinson WA; McCarter M; Pearlman N; O'Day SJ; Anderson C; Amatruda TT; Baron A; Zeng C; Becker M; Dollarhide S; Matijevich K; Gonzalez R
J Clin Oncol; 2006 Jul; 24(19):3157-63. PubMed ID: 16809738
[TBL] [Abstract][Full Text] [Related]
8. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
Keilholz U; Stoter G; Punt CJ; Scheibenbogen C; Lejeune F; Eggermont AM
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S22-8. PubMed ID: 9457389
[TBL] [Abstract][Full Text] [Related]
9. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.
Legha SS; Ring S; Eton O; Bedikian A; Plager C; Papadopoulos N
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S9-15. PubMed ID: 9457387
[TBL] [Abstract][Full Text] [Related]
10. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R;
Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
[TBL] [Abstract][Full Text] [Related]
11. Practical guidelines for the management of biochemotherapy-related toxicity in melanoma.
Buzaid AC; Atkins M
Clin Cancer Res; 2001 Sep; 7(9):2611-9. PubMed ID: 11555571
[TBL] [Abstract][Full Text] [Related]
12. Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?
Hofmann MA; Sterry W; Trefzer U
Jpn J Clin Oncol; 2007 Mar; 37(3):224-9. PubMed ID: 17472972
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous interleukin-2 and interferon-alpha therapy associated with cisplatin monochemotherapy in the treatment of metastatic melanoma.
Andrès P; Cupissol D; Guillot B; Avril MF; Drèno B
Eur J Dermatol; 1998 Jun; 8(4):235-9. PubMed ID: 9649695
[TBL] [Abstract][Full Text] [Related]
14. Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
Thompson JA; Gold PJ; Fefer A
Semin Oncol; 1997 Feb; 24(1 Suppl 4):S44-8. PubMed ID: 9122734
[TBL] [Abstract][Full Text] [Related]
15. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
16. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
Kretschmer L; Helmbold P; Emmert S; Marsch WC
Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous interleukin-2 and interferon-alpha plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: a phase II study.
Schmidt H; Geertsen PF; Fode K; Rytter C; Bastholt L; von der Maase H
Melanoma Res; 2000 Feb; 10(1):66-77. PubMed ID: 10711642
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
Garbe C
Melanoma Res; 1993 Aug; 3(4):291-9. PubMed ID: 7693093
[TBL] [Abstract][Full Text] [Related]
19. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
Liu D; O'Day SJ; Yang D; Boasberg P; Milford R; Kristedja T; Groshen S; Weber J
Clin Cancer Res; 2005 Feb; 11(3):1237-46. PubMed ID: 15709194
[TBL] [Abstract][Full Text] [Related]
20. Biochemotherapy of melanoma.
Keilholz U
Forum (Genova); 2003; 13(2):158-65; quiz 189. PubMed ID: 14732882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]